SHAKNEUTRAL

SHAK P/E Ratio Analysis

57.2x

Updated 830h ago·SEC filings & market data

Key Takeaway

The P/E ratio of 57.2x means investors pay $57.20 for every $1 of the company's trailing earnings, a premium valuation that requires strong future growth to justify.

Sector Performance

88th percentile

SHAK

57.2x

Sector Median

22.9x

Sector Avg

34.3x

Prior Period

54.9x(Aug 2026)

↓ Declining
📊

Deep Analysis

The P/E ratio of 57.2x means investors pay $57.20 for every $1 of the company's trailing earnings, a premium valuation that requires strong future growth to justify.

This sits well above the sector median of 22.9x, placing SHAK in the 88th percentile among peers, meaning only 12% of comparable stocks trade at a higher multiple. The multiple expanded 4.1% quarter-over-quarter from 54.9x, showing the earnings valuation is increasing despite the already elevated starting point. The combination of a high level and a rising trend indicates growth expectations are being bid up further, which increases the risk of a sharp correction if results underdeliver. This pricing pressure contradicts the NEUTRAL verdict's implication of balanced risk-reward, as the current entry point offers limited margin of safety.

Frequently Asked Questions

What does the P/E Ratio tell investors about SHAK?

Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.

How is the P/E Ratio calculated?

P/E Ratio is calculated as: Price / EPS.

The Formula

Price / EPS

Why It Matters

Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.

Advertisement

Master SHAK's Valuation

Get the complete institutional research report covering all fundamental and technical metrics.

View full SHAK research report →

Free account — no credit card

SHAK

57.2x

Sector Median

22.9x

Sector Avg

34.3x

How SHAK's P/E Ratio compares to sector peers.

Not financial advice. Research tool only. Data may be delayed.